RS-2023-00218035

A First-in-Class Treatment for Non-alcoholic Steatohepatitis

JD Bioscience, Inc.

JD BIOSCIENCE

METABOLIC | **Phase 1**

Product Type	Small molecule (Code Name: GM-60106)
Indication	NASH (Non-alcoholic steatohepatitis)
Target	5-hydroxytryptamine(5-HT) receptor 2A (HTR2A)
MoA(Mechanism of Action)	The expression of HTR2A is increased in patients with NASH, and this upregulation is directly linked to enhanced lipogenesis, inflammation, and fibrosis in the liver. HTR2A inhibition using GM-60106 blocks these effects
Competitiveness	Direct mechanism for NASH-related fibrosis - Suppressing HTR2A with GM-60106 can directly deactivate hepatic stellate cells and hepatocytes, critical for liver fibrosis and lipogenesis, respectively • Superior efficacy, kinetics, and safety - Stronger efficacy for liver fibrosis and inflammation compared to other drug designs in vivo - Optimal PK profiles for an oral administrative drugs - Safe from CNS-mediated safety issues
Development Stage	Phase 1(expected to be completed at Dec 2023)
Route of Administration	Oral administration

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund